Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Mylan gets Humira-related IP from AbbVie

Executive Summary

AbbVie Inc. licensed Mylan NV non-exclusive rights to patents and intellectual property relating to Humira (adalimumab) in the US and certain other countries (excluding Europe) where AbbVie has IP, which Mylan will use in its development of a Humira biosimilar.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register